Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Gross Profit (2018 - 2023)

Serina Therapeutics' Gross Profit history spans 6 years, with the latest figure at $55000.0 for Q4 2023.

  • For Q4 2023, Gross Profit rose 685.71% year-over-year to $55000.0; the TTM value through Dec 2023 reached $102000.0, up 385.71%, while the annual FY2023 figure was $102000.0, 385.71% up from the prior year.
  • Gross Profit for Q4 2023 was $55000.0 at Serina Therapeutics, up from $34000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $470000.0 in Q4 2019 and bottomed at -$908000.0 in Q4 2020.
  • The 5-year median for Gross Profit is $30000.0 (2021), against an average of $67100.0.
  • The largest annual shift saw Gross Profit crashed 293.19% in 2020 before it soared 750.0% in 2023.
  • A 5-year view of Gross Profit shows it stood at $470000.0 in 2019, then plummeted by 293.19% to -$908000.0 in 2020, then soared by 102.86% to $26000.0 in 2021, then crashed by 73.08% to $7000.0 in 2022, then soared by 685.71% to $55000.0 in 2023.
  • Per Business Quant, the three most recent readings for SER's Gross Profit are $55000.0 (Q4 2023), $34000.0 (Q3 2023), and $4000.0 (Q2 2023).